View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Ascendis Pharma Reports First Quarter 2024 Financial Results

Ascendis Pharma Reports First Quarter 2024 Financial Results — Rollout of YORVIPATH® initiated in Germany and Austria, with an estimated 55 doctors writing prescriptions and ~100 patients receiving commercial product as of March 31 — TransCon™ PTH (palopegteriparatide) PDUFA date of May 14, 2024, for adults with hypoparathyroidism. If approved, U.S. launch planned in Q3 — TransCon CNP (navepegritide) pivotal ApproaCH Trial on track for topline results in Q4 2024 — SKYTROFA® Q1 revenue more than doubled year-over-year to €65 million; Q1 operating expenses fell by 20% year-over-year to €13...

 PRESS RELEASE

Ascendis Pharma to Report First Quarter 2024 Financial Results and Pro...

Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024 COPENHAGEN, Denmark, April 25, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report first quarter 2024 financial results and provide a business update on Thursday, May 2, 2024, after the close of the U.S. financial markets. Ascendis Pharma will also host a conference call and live webcast on May 2, 2024, at 4:30 p.m. Eastern Time (ET) to discuss its first quarter 2024 financial results. Those who would like to participate may access the live we...

 PRESS RELEASE

United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Gre...

United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism COPENHAGEN, Denmark, April 24, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the United Kingdom’s Medicines & Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for YORVIPATH® (palopegteriparatide; developed as TransCon™ PTH) in Great Britain as a parathyroid hormone (PTH) replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism, and has also granted YOR...

David Carlson ... (+8)
  • David Carlson
  • David Nierengarten
  • Dennis Pak
  • Laura Chico
  • Martin Fan
  • Ritika Das
  • Robert Driscoll
  • Sam Ravina
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
VRTX VERTEX PHARMACEUTICALS INCORPORATED
SRPT SAREPTA THERAPEUTICS INC.
SGMO SANGAMO THERAPEUTICS INC.
SAGE SAGE THERAPEUTICS INC.
RGNX REGENXBIO INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PCRX PACIRA BIOSCIENCES INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MNKD MANNKIND CORP.
LL LUMBER LIQUIDATORS HOLDINGS INC.
KURA KURA ONCOLOGY INC.
HD HOME DEPOT INC.
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
CMRX CHIMERIX INC
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
TSC TRISTATE CAPITAL HOLDINGS INC
UTHR UNITED THERAPEUTICS CORPORATION
CLSD CLEARSIDE BIOMEDICAL INC
NTLA INTELLIA THERAPEUTICS INC.
PK PARK HOTELS & RESORTS INC.
ANAB ANAPTYSBIO INC.
KALA KALA PHARMACEUTICALS INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
OVID OVID THERAPEUTICS
GTHX G1 THERAPEUTICS
ALPN ALPINE IMMUNE SCIENCES
VRNA VERONA PHARMA ADS
SE SEA ADS
AMD ADVANCED MICRO DEVICES INC.
APLS APELLIS PHARMACEUTICALS
UBX UNITY BIOTECHNOLOGY
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
LQDA LIQUIDIA CORPORATION
REPL REPLIMUNE GROUP
AX AXOS FINANCIAL INC.
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
IMUX IMMUNIC INC
GOSS GOSSAMER BIO
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
APRE APREA THERAPEUTICS
AQST AQUESTIVE THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
RVMD REVOLUTION MEDICINES
PASG PASSAGE BIO
ACET ADICET BIO INC
ASO ACADEMY SPORTS AND OUTDOORS
KROS KEROS THERAPEUTICS
ITOS ITEOS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
BEAM BEAM THERAPEUTICS
GBIO GENERATION BIO
PRAX PRAXIS PRECISION MEDICINES
COGT COGENT BIOSCIENCES INC
VOR VOR BIOPHARMA
NUVB NUVATION BIO INC (A)
CGEM CULLINAN ONCOLOGY INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
ELEV ELEVATION ONCOLOGY
OMGA OMEGA THERAPEUTICS
SBTX SILVERBACK THERAPEUTICS
TNGX TANGO THERAPEUTICS
LBPH INC
IKNA LONGBOARD PHARMACEUTICALS
TCRX IKENA ONCOLOGY INC
VERA TSCAN THERAPEUTICS INC
HOWL VERA THERAPEUTICS INC
GLUE WEREWOLF THERAPEUTICS INC
AVTE MONTE ROSA THERAPEUTICS INC
CMPX AEROVATE THERAPEUTICS INC
GMTX COMPASS THERAPEUTICS
JANX GEMINI THERAPEUTICS INC
VIGL JANUX THERAPEUTICS INC
MLTX VIGIL NEUROSCIENCE INC
TYRA MOONLAKE IMMUNOTHERAPEUTICS
PEPG TYRA BIOSCIENCES INC
HR PEPGEN INC
EWTX HEALTHCARE TRUST OF AMERICA INC.
PRME EDGEWISE THERAPEUTICS INC
OCS PRIME MEDICINE INC
APGE OCULIS HOLDING AG
DNTH APOGEE THERAPEUTICS INC
DIANTHUS THERAPEUTICS INC
Wedbush Research
  • Wedbush Research
 PRESS RELEASE

Ascendis Pharma to Participate in the Leerink Partners Global Biopharm...

Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024 COPENHAGEN, Denmark, March 04, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Leerink Partners Global Biopharma Conference 2024 on Monday, March 11, 2024 at 2:00 p.m. ET in Miami, Florida. A live webcast of the fireside chat will be available via the Investors & News section of the Ascendis Pharma website at investors.ascendispharma.com. A webcast replay will also be available on this website shortly af...

Wedbush Research
  • Wedbush Research
TPX TEMPUR SEALY INTERNATIONAL INC
MTB M&T BANK CORPORATION
STZ CONSTELLATION BRANDS INC. CLASS A
UBI UBISOFT ENTERTAINMENT SA
QRVO QORVO INC.
DPZ DOMINO'S PIZZA INC.
WING WINGSTOP INC.
WDC WESTERN DIGITAL CORPORATION
TXRH TEXAS ROADHOUSE INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
SBUX STARBUCKS CORPORATION
QCOM QUALCOMM INC
PSTG PURE STORAGE INC. CLASS A
PEGA PEGASYSTEMS INC.
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
MGPI MGP INGREDIENTS INC.
JACK JACK IN THE BOX INC.
INTC INTEL CORPORATION
IMAX IMAX CORPORATION
GERN GERON CORP.
FHN FIRST HORIZON CORPORATION
ETSY ETSY INC.
EPAM EPAM SYSTEMS INC.
DECK DECKERS OUTDOOR CORPORATION
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
CAKE CHEESECAKE FACTORY INCORPORATED
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
NFLX NETFLIX INC.
OSTK OVERSTOCK.COM INC.
WD WALKER & DUNLOP INC.
BJRI BJ'S RESTAURANTS INC.
SWKS SKYWORKS SOLUTIONS INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
DRI DARDEN RESTAURANTS INC.
UTHR UNITED THERAPEUTICS CORPORATION
FCNCA FIRST CITIZENS BANCSHARES INC. CLASS A
CELH CELSIUS HOLDINGS INC.
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
RCUS ARCUS BIOSCIENCES
TENB TENABLE HOLDINGS
SMCI SUPER MICRO COMPUTER
UFPI INC.
STX UFP INDUSTRIES INC.
MTTR SEAGATE TECHNOLOGY HLDGS PLC
ALIT GORES HOLDINGS II INC
GFS FOLEY TRASIMENE ACQUISITION CORP
MLTX GLOBALFOUNDRIES INC
BROS MOONLAKE IMMUNOTHERAPEUTICS
DUTCH BROS INC
Andreas Argyrides ... (+10)
  • Andreas Argyrides
  • Caroline Pocher
  • David Carlson
  • David Nierengarten
  • Dennis Pak
  • Laura Chico
  • Martin Fan
  • Ritika Das
  • Robert Driscoll
  • Sam Ravina
Andreas Argyrides ... (+3)
  • Andreas Argyrides
  • Caroline Pocher
  • Liana Moussatos
 PRESS RELEASE

Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results

Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results Launch of TransCon™ PTH underway with full commercial availability in Germany and Austria; U.S. PDUFA date of May 14, 2024TransCon CNP pivotal ApproaCH Trial on track for topline results in Q4 2024Total Q4 revenue of €138 million including SKYTROFA® revenue of €64 million; Q4 operating expenses of €155 million Conference call today at 4:30 pm ET COPENHAGEN, Denmark, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the fourth quarter and full year ended December 31, ...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch